488 results on '"Towse, Adrian"'
Search Results
2. Implementing an EU pull incentive for antimicrobial innovation and access: blueprint for action
3. It Takes 2 to Tango. Setting Out the Conditions in Which Performance-Based Risk-Sharing Arrangements Work for Both Parties
4. The Allocation of the Economic Value of Second-Generation Antipsychotics Over the Product Life Cycle: The Case of Risperidone in Sweden and the United Kingdom
5. Supply-Side Cost-Effectiveness Thresholds: Questions for Evidence-Based Policy
6. Why We Need a New Outcomes-Based Value Attribution Framework for Combination Regimens in Oncology
7. Considering Severity in Health Technology Assessment: Can We Do Better?
8. Estimating health system opportunity costs: the role of non-linearities and inefficiency
9. Hemophilia Gene Therapy Value Assessment: Methodological Challenges and Recommendations
10. Economic evaluation of meningococcal vaccines: considerations for the future
11. How Should the World Pay for a Coronavirus Disease (COVID-19) Vaccine?
12. It takes two to tango. Setting out the conditions in which performance-based risk-sharing arrangements work for both parties.
13. Is rate of return pricing a useful approach when value-based pricing is not appropriate?
14. Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcare
15. Reconciling ACEA and MCDA: is there a way forward for measuring cost-effectiveness in the U.S. healthcare setting?
16. Challenges in valuing and paying for combination regimens in oncology: reporting the perspectives of a multi‐stakeholder, international workshop
17. Specific Value Assessment Considerations
18. Uncertainty and Cures: Discontinuation, Irreversibility, and Outcomes-Based Payments: What Is Different About a One-Off Treatment?
19. Paying for Cures: Perspectives on Solutions to the “Affordability Issue”
20. Approaches to Aggregation and Decision Making—A Health Economics Approach: An ISPOR Special Task Force Report [5]
21. A Health Economics Approach to US Value Assessment Frameworks—Summary and Recommendations of the ISPOR Special Task Force Report [7]
22. Objectives, Budgets, Thresholds, and Opportunity Costs—A Health Economics Approach: An ISPOR Special Task Force Report [4]
23. Genetic Screening, Health Care and the Insurance Industry: Should Genetic Information Be Made Available to Insurers?
24. A theory on ICER pricing and optimal levels of cost-effectiveness thresholds: a bargaining approach
25. Differential Pricing for Pharmaceuticals: Reconciling Access, R&D and Patents
26. Time for a change in how new antibiotics are reimbursed: Development of an insurance framework for funding new antibiotics based on a policy of risk mitigation
27. Value assessment in precision cancer medicine
28. Toward a Broader Concept of Value: Identifying and Defining Elements for an Expanded Cost-Effectiveness Analysis
29. Establishing a reasonable price for an orphan drug
30. Fostering incentives for research, development, and delivery of interventions for neglected tropical diseases: lessons from malaria
31. Placing a value on increased flexible vaccine manufacturing capacity for future pandemics
32. El uso del pago por resultados para los fármacos: ¿Puede mejorar los incentivos para la innovación?
33. The use of pay-for-performance for drugs: Can it improve incentives for innovation?
34. The Societal Value of Vaccines: Expert-Based Conceptual Framework and Methods Using COVID-19 Vaccines as a Case Study
35. The cost-per-QALY threshold in England: Identifying structural uncertainty in the estimates
36. The Societal Value of Vaccines: Expert-Based Conceptual Framework and Methods Using COVID-19 Vaccines as A Case Study
37. Real Option Value: Should We Opt In or Out?
38. Reforming the Cancer Drug Fund
39. Orphan drugs policies: a suitable case for treatment
40. Alternative funding models for medical innovation: the role of product development partnerships in product innovation for infectious diseases.
41. Biosimilars: How Can Payers Get Long-Term Savings?
42. Economic Incentives for Evidence Generation: Promoting an Efficient Path to Personalized Medicine
43. Performance-Based Risk-Sharing Arrangements—Good Practices for Design, Implementation, and Evaluation: Report of the ISPOR Good Practices for Performance-Based Risk-Sharing Arrangements Task Force
44. Challenges in the Development and Reimbursement of Personalized Medicine—Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Special Interest Group
45. Is it time to reconsider the role of patient co-payments for Pharmaceuticals in Europe?
46. Prospective Observational Studies to Assess Comparative Effectiveness: The ISPOR Good Research Practices Task Force Report
47. Alternative funding models for medical innovation: the role of product development partnerships in product innovation for infectious diseases
48. Working towards a sustainable, healthy market for vaccines: A framework to support evidence-based policymaking
49. Should NICE's Threshold Range for Cost per QALY Be Raised?
50. Should We Pay for Scientific Knowledge Spillovers?: The Underappreciated Value of “Failed” R&D Efforts
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.